How Dr. Clay Siegall Pioneered The Next Generation Of Cancer Drugs

Dr. Clay Siegall has been a trailblazer in developing targeted cancer therapies. Older conventional cancer treatment involves surgery, chemotherapy, radiation, and drugs that kill healthy and unhealthy cells alike. The next generation of drugs being designed by visionaries like Dr. Clay Siegall involves drugs that specifically target and kill only cancer cells while leaving healthy cells alone. This type of treatment is not only more tolerable for the patient it is also far more effective at irradicating cancer from their body.

It was in 1998 that Dr. Clay Siegall founded Seattle Genetics. As Chief Executive Officer he has been at the forefront of using antibody-drug conjugates to develop cancer drugs. Their first cancer drug, Adcetris, was approved by the FDA to treat cancer and is now being used in a number of countries around the world. It now has multiple approved indications by the FDA. Seattle Genetics also has over 20 other antibody-drug conjugate based drugs in their pipeline at different stages of development. These are researched and developed at Seattle Genetics along with the strategic partnerships that Dr. Clay Siegall has established with other biotechnology companies such as Bayer, Pfizer, Genentech, and other industry players.

Making next generation drugs is both very expensive and very risky. Only about 1 in 10 candidate drugs attain FDA approval. Creating a drug takes years of research and a huge amount of money. Due to this Dr. Clay Siegall has said that its great when your pharmaceutical drug company’s drug is approved because it helps people and makes the company a large amount of money. Due to uncertainties surrounding drug development, Seattle Genetics has other revenue sources available which Dr. Clay Siegall has been a very important part of developing.

Before founding Seattle Genetics, Dr. Clay Siegall spent several years in medical drug research and development. He started out working for the National Cancer Institute before joining Bristol-Myers Squibb as a Senior Researcher. His job at Bristol-Myers Squibb was located at their Seattle offices which is what first drew him to that region of the country. As the greater Seattle area has a thriving biotechnology scene he decided to headquarter his new company in the region.